These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23176347)

  • 1. Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components.
    Sigle JP; Infanti L; Studt JD; Martinez M; Stern M; Gratwohl A; Passweg J; Tichelli A; Buser AS
    Transfusion; 2013 Aug; 53(8):1788-97. PubMed ID: 23176347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment.
    Knutson F; Osselaer J; Pierelli L; Lozano M; Cid J; Tardivel R; Garraud O; Hervig T; Domanovic D; Cukjati M; Gudmundson S; Hjalmarsdottir IB; Castrillo A; Gonzalez R; Brihante D; Santos M; Schlenke P; Elliott A; Lin JS; Tappe D; Stassinopoulos A; Green J; Corash L
    Vox Sang; 2015 Nov; 109(4):343-52. PubMed ID: 25981525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemostatic function and transfusion efficacy of apheresis platelet concentrates treated with gamma irradiation in use for thrombocytopenic patients.
    Zhu M; Xu W; Wang BL; Su H
    Transfus Med Hemother; 2014 Jun; 41(3):189-96. PubMed ID: 25053932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomized study.
    de Wildt-Eggen J; Nauta S; Schrijver JG; van Marwijk Kooy M; Bins M; van Prooijen HC
    Transfusion; 2000 Apr; 40(4):398-403. PubMed ID: 10773049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology.
    Mirasol Clinical Evaluation Study Group
    Transfusion; 2010 Nov; 50(11):2362-75. PubMed ID: 20492615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of platelet additive solution-E stored platelet concentrates.
    Spelmink SE; Jager ST; van de Watering L; van der Meer PF; van Gammeren AJ; Wiersum-Osselton JC; Klei TRL; Kerkhoffs JH;
    Transfusion; 2023 Dec; 63(12):2273-2280. PubMed ID: 37909172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Observational study of corrected count increments after transfusion of platelets treated with riboflavin pathogen reduction technology in additive solutions.
    Drawz SM; Marschner S; Yañez M; García de Coca A; Feys HB; Deeren D; Coene J
    Transfusion; 2015 Jul; 55(7):1745-51. PubMed ID: 25702711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia.
    Slichter SJ; Raife TJ; Davis K; Rheinschmidt M; Buchholz DH; Corash L; Conlan MG
    Transfusion; 2006 May; 46(5):731-40. PubMed ID: 16686840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of amotosalen-ultraviolet A pathogen-inactivated platelets stored for up to 7 days.
    Infanti L; Holbro A; Passweg J; Bolliger D; Tsakiris DA; Merki R; Plattner A; Tappe D; Irsch J; Lin JS; Corash L; Benjamin RJ; Buser A
    Transfusion; 2019 Nov; 59(11):3350-3361. PubMed ID: 31574181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomic analysis of platelets treated with gamma irradiation versus a commercial photochemical pathogen reduction technology.
    Marrocco C; D'Alessandro A; Girelli G; Zolla L
    Transfusion; 2013 Aug; 53(8):1808-20. PubMed ID: 23305084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.
    Lozano M; Knutson F; Tardivel R; Cid J; Maymó RM; Löf H; Roddie H; Pelly J; Docherty A; Sherman C; Lin L; Propst M; Corash L; Prowse C
    Br J Haematol; 2011 May; 153(3):393-401. PubMed ID: 21418180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogen reduction of double-dose platelet concentrates from pools of eight buffy coats: Product quality, safety, and economic aspects.
    Rosskopf K; Helmberg W; Schlenke P
    Transfusion; 2020 Sep; 60(9):2058-2066. PubMed ID: 32619068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation.
    Hechler B; Ohlmann P; Chafey P; Ravanat C; Eckly A; Maurer E; Mangin P; Isola H; Cazenave JP; Gachet C
    Transfusion; 2013 Jun; 53(6):1187-200. PubMed ID: 23067365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient and product factors affecting platelet transfusion results.
    Heim D; Passweg J; Gregor M; Buser A; Theocharides A; Arber C; Meyer-Monard S; Halter J; Tichelli A; Gratwohl A
    Transfusion; 2008 Apr; 48(4):681-7. PubMed ID: 18208413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to random apheresis platelets versus HLA-selected platelets versus pooled platelets in HLA-sensitized patients.
    Gavva C; Barroso J; Gernsheimer T; Metcalf RA; Warner P; Pagano MB
    Transfusion; 2019 Jul; 59(7):2276-2281. PubMed ID: 31032968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set.
    Janetzko K; Cazenave JP; Klüter H; Kientz D; Michel M; Beris P; Lioure B; Hastka J; Marblie S; Mayaudon V; Lin L; Lin JS; Conlan MG; Flament J
    Transfusion; 2005 Sep; 45(9):1443-52. PubMed ID: 16131376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes (CME).
    Wiita AP; Nambiar A
    Transfusion; 2012 Oct; 52(10):2146-54. PubMed ID: 23113654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light.
    Murphy S; Snyder E; Cable R; Slichter SJ; Strauss RG; McCullough J; Lin JS; Corash L; Conlan MG;
    Transfusion; 2006 Jan; 46(1):24-33. PubMed ID: 16398727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogen-reduced platelets for the prevention of bleeding.
    Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF
    Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transfusion of pathogen-reduced platelet components without leukoreduction.
    Sim J; Tsoi WC; Lee CK; Leung R; Lam CCK; Koontz C; Liu AY; Huang N; Benjamin RJ; Vermeij HJ; Stassinopoulos A; Corash L; Lie AKW
    Transfusion; 2019 Jun; 59(6):1953-1961. PubMed ID: 30919465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.